Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients

Pancreatic cancer is one of the most lethal solid tumors. In many European countries gemcitabine plus nab-paclitaxel is the preferred first-line treatment. An increasing number of patients are eligible for second-line therapy, but the best regimen is still controversial. This study aimed to evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Merz, Valeria, Cavaliere, Alessandro, Messina, Carlo, Salati, Massimiliano, Zecchetto, Camilla, Casalino, Simona, Milella, Michele, Caffo, Orazio, Melisi, Davide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281137/
https://www.ncbi.nlm.nih.gov/pubmed/32366019
http://dx.doi.org/10.3390/cancers12051131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281137/
https://www.ncbi.nlm.nih.gov/pubmed/32366019
http://dx.doi.org/10.3390/cancers12051131

Ejemplares similares